The Latest News from GenNext Technologies

GenNext Technologies Introduces Protein Footprinting Products to Japan through Kiko Tech Co., LTD.

​HALF MOON BAY, Calif. – May 11, 2022 – GenNext Technologies, Inc. (GenNext), announced today a partnership with Kiko Tech Co., Ltd., to provide Flash Oxidation (Fox™) Protein Footprinting Systems to the Japanese life science research market.

Under an agreement between the parties, Kiko Tech has been appointed sole distributor for the GenNext product portfolio for Japan. Together, GenNext and Kiko Tech will provide sales and marketing, customer service, technical support, training, and related logistical efforts for Flash Oxidation (Fox™) Protein Footprinting Systems.

Kiko Tech is a premier distributor of state-of-the-art instruments and reagents for molecular diagnostics, proteomics, applied testing, pharmaceutical, and academic research since its establishment in 1974. The Kiko Tech team is excited about the opportunity to introduce the Japanese scientific community to the novel Fox™-based approach to Hydroxyl Radical Protein Footprinting (HRPF).

GenNext introduced Fox-Based HRPF to the market as a disruptive, intrinsically scalable approach to protein Higher Order Structure (HOS) analysis to increase the effectiveness and minimize adverse drug reactions of biopharmaceuticals. This protein footprinting method, originally demonstrated in a 2021 Journal of the American Society of Mass Spectrometry paper, is experiencing rapid adoption in North America and Europe by leading biopharmaceutical companies.

A GenNext HRPF study can address scientific questions that previously required difficult, expensive, and time-consuming hydrogen deuterium exchange, nuclear magnetic resonance, X-ray crystallography or cryo-electron microscopy experiments. Alternatively, researchers would have to combine multiple techniques such as circular dichroism spectroscopy, size-exclusion chromatography, and light-scattering analysis to generate less informative results than by conducting a single series of GenNext HRPF experiments.

“The GenNext team is very pleased to collaborate with Kiko Tech to introduce our products to Japan as part of our global expansion program,” said Scot R. Weinberger, CEO and Founder of GenNext. He continued, “We anticipate that Japanese biopharmaceutical researchers will be receptive to and adopt HRPF as a new standard to elucidate HOS, and we have found the perfect partner in Kiko Tech who are already active in this area.”

“Kiko Tech is excited to bring GenNext products to the Japanese life science community,” said Shigenobu Fukushima, General Manager of Kiko Tech. “GenNext’s products move HOS beyond the limitations inherent in current techniques, enabling our customers to discover and develop biopharmaceuticals faster and with higher quality.”

In the USA, GenNext will be presenting the capabilities of its platform at the upcoming American Society of Mass Spectrometry meeting (June 5-9, 2022).  At the same time, Japanese researchers will be able to learn about the HRPF technique and GenNext products at the Japanese Society of Protein Sciences meeting.

For more information, please see our website at www.gnxtech.com

About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health. www.gnxtech.com

About Kiko Tech Co., LTD.
With headquarters in Osaka, Japan and offices in Tokyo, Tsukuba City, and Kanagawa, Kiko Tech Co., Ltd. is a premier distributor of scientific products that was established in 1974. It offers a wide range of high-quality products that are used in life science pure and applied research including diagnostics, biopharmaceutical development and in university and government settings. It’s products and services are offered throughout Japan using its direct staff as well as a network of distributors.
https://kiko-tech.co.jp/about_en/

Contact
Scot R. Weinberger
Founder and CEO
[email protected]
650-726-1060

GenNext Technologies Announces $2.5M Grant Award to Commercialize In-Cell Protein Footprinting Instrumentation

HALF MOON BAY, Calif. – March 24, 2022 – GenNext Technologies, Inc., a growth-stage company providing biopharmaceutical drug discovery systems and services, announced today the receipt of a two year, Phase II SBIR grant for a project titled “In-Cell Automated Flash Oxidation (IC-AutoFox™) Protein Footprinting System.” The grant was awarded by the National Institute of General Medical Systems (NIGMS) of the U.S. Department of Health and Human Services. The purpose of the grant is to extend GenNext’s breakthrough Hydroxyl Radical Protein Footprinting (HRPF) technology and methods to studies involving living cells.

This award of $2.5 million brings total funding from NIGMS for the GenNext platform to $9.5 million.

The Flash Oxidation (Fox™) Protein Footprinting System is currently being used by the biopharmaceutical industry to perform Higher Order Structure (HOS) analysis of proteins with an emphasis on biologic therapeutics, the most rapidly growing segment in this area. The Fox System helps researchers develop safer and more effective biotherapeutics by revealing important information about protein interactions and structural changes.

With the support of this NIGMS grant, GenNext can now leverage its proprietary technology and considerable knowhow to develop a fully automated platform that will study drug induced HOS structure changes within living cells, with its first system designed for in vivo protein footprinting studies. This includes drug candidate activity for G protein-coupled receptor therapeutics and ion channel blockers. Thus, in-cell protein footprinting technology will, for the first time, empower scientists to survey the complex milieu of biological responses to therapeutic candidates. By studying drug response within living cells, researchers will obtain a more accurate depiction of efficacy and potential side effects.

“With this award, we will complete our in-cell protein footprinting R&D program, culminating in a revolutionary new tool to study protein structure, protein interactions, and drug interactions in living cells. Soon, researchers will study living cells with a new level of simplicity and elegance, while generating unprecedented levels of actionable data,” said Scot R. Weinberger, Founder and CEO of GenNext. “We’re truly delighted to receive our tenth NIGMS grant award as further validation of our leadership in commercializing novel and robust protein footprinting technology.”

“It’s very exciting to watch as the GenNext platform is being adopted by many different laboratories and emerges as an essential method in structural biology labs,” notes Professor Lisa Jones from University of California San Diego and inventor of in vivo protein footprinting. “I look forward to collaborating with the GenNext team to produce the world’s first in-cell protein footprinting system. As demonstrated in our laboratory, the application of this important technique to living tissues and small organisms will enable, for the first time, HRPF studies of storage diseases.”

For more information, please see our website at www.gnxtech.com

About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our powerful, compact, and cost-effective platform enables researchers to conduct reproducible Higher Order Structure experiments quickly, easily, and safely. We help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. Ultimately, our mission is to enable structural biology researchers to discover and develop drug therapies that improve human health. www.gnxtech.com

Contact
Scot R. Weinberger

Founder and CEO
[email protected]
650-726-1060

 

GenNext Technologies Announces its Second Key US Protein Footprinting Patent

HALF MOON BAY, Calif.December 9, 2021Life Science NewswireGenNext Technologies, Inc., a growth-stage company providing instrumentation, software, and services, announced today that it has earned a second seminal patent protecting the company’s novel radical dosimetry technology which vastly improves the utility of protein footprinting for the study of biopharmaceutical structure, function, and safety.

The United States Patent and Trademark Office (USPTO) has issued Patent US 11,181,529 B2: “Radical Dosimetry for the Analysis of Biopharmaceuticals and Biological Molecules.” This patent protects the company’s novel core technology and Intellectual Property (IP) that enables real-time assessment of protein footprinting chemical reactions with robust accuracy and reproducibility, while substantially improving ease-of-use.

Specifically, this patent protects GenNext’s novel approach to determining protein tertiary and quaternary structure, along with associated conformation, of a given biomolecule. This insight enables researchers to develop superior biosimilars and biotherapeutics that limit or eliminate adverse drug reactions while increasing the drug’s efficacy.

The mission of GenNext is to help researchers elucidate, through protein footprinting, the critical role that Higher Order Structure (HOS) plays in the safety, stability, and function of biotherapeutics. Although protein footprinting promised to revolutionize drug discovery, adoption has been slow due to the inherent complexity, dangerous instrumentation, and reproducibility challenges of older methods.

“With the launch of our Flash Oxidation (Fox™) System and Services in 2019, we solved these adoption problems by increasing the sensitivity, reproducibility, and ease-of-use of protein footprinting,” said Scot R. Weinberger, Founder and CEO of GenNext. “Now that a full-solution HOS technology platform and service is available to the structural biology research community, we’ve seen a surging adoption of this powerful technique by leading US and EU biopharmaceutical companies. We’re delighted to receive our second US patent as validation of our leadership in commercializing novel and robust protein footprinting technology.”

For more information, please see our website at www.gnxtech.com

 About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to pharmaceutical researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our disruptive products are aimed at improving structural biology-focused research. Ultimately, we seek to help our customers accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. www.gnxtech.com

Contact

Scot R. Weinberger

Founder and CEO

[email protected]

650-726-1060

GenNext Technologies Announces NIH Grant Funding of Nearly $7M Leads to a Seminal Protein Footprinting Patent

HALF MOON BAY, Calif.April 28, 2021Life Science Newswire  – GenNext Technologies, Inc., a growth-stage company that provides instrumentation, software, and services to structural biology researchers within the biopharmaceutical industry, announced today that nearly $7M (US) in NIH grant awards has led to a seminal US patent for its novel technology that vastly improves the utility of protein footprinting for the study of biopharmaceutical higher order structure.

GenNext Technologies is honored to have earned a total of nine National Institute of General Medical Sciences grant awards to support the development of their breakthrough Hydroxyl Radical Protein Footprinting (HRPF) instrumentation and data processing software, known as the Flash Oxidation (Fox™) Protein Footprinting System.

This powerful, compact, and cost-effective platform enables researchers to conduct reproducible HRPF experiments quickly, easily, and safely. The Fox™ System reveals important information about protein interactions and structural changes, leading to the development of safer and more effective biotherapeutics.

A GenNext HRPF study can answer scientific questions that previously required difficult,  expensive, and time-consuming nuclear magnetic resonance, X-ray crystallography or cryo-electron microscopy experiments. Alternatively, researchers would have to combine multiple techniques such as circular dichroism spectroscopy, size-exclusion chromatography, and light-scattering analysis to generate less informative results than running a single GenNext HRPF experiment.

In recognition of GenNext’s novel technology, the United States Patent and Trademark Office issued Patent US 10,816,468 B2 for “Flash Photo-Oxidation Device and Higher Order Structural Analysis.” This patent protects the company’s proprietary technology and knowhow that enable, for the first time, real-time assessment of photo-chemical reactions and provide robust reproducibility, while substantially improving ease-of-use.

The mission of GenNext is to help researchers quickly and easily elucidate the critical role that protein structure plays in the safety, stability, and biological function of biotherapeutics,” said Scot R. Weinberger, Founder and CEO of GenNext. “By integrating our novel instrumentation and data processing software into their structural biology workflow, our customers can answer key drug development questions in days rather than weeks or months. We look forward to helping our customers accelerate the development of safer and more effective drugs to improve human health.

GenNext’s new approach is described in a peer-reviewed article recently published in the Journal of the American Society for Mass Spectrometry, The Flash Oxidation (FOX) System: A Novel Laser-Free Fast Photochemical Oxidation Protein Footprinting Platform, authored by researchers from GlycoScientific, University of Mississippi, University of Georgia, and GenNext Technologies

Recently, GenNext teamed-up with its alliance partner, NeoProteomics, to produce a five-part seminar series on the science of protein footprinting including applications, methods development, techniques, and data analysis. The series was created and presented by structural biology luminaries who are also members of the GenNext Scientific Advisory Board: Professors Mark Chance (Case Western Reserve), Michael Gross (Washington University in St. Louis), Joshua Sharp (University of Mississippi), and Lisa Jones (University of Maryland). These seminars are available for on-demand viewing on the GenNext website.

For more information, please see our website at www.gnxtech.com

 

About GenNext Technologies
Located in the San Francisco Bay Area, GenNext Technologies, Inc., is a growth-stage company that provides instrumentation, software, and services to researchers investigating biopharmaceutical structure, interactions, folding, aggregation, formulation, and delivery. Our disruptive products and services are aimed at improving structural biology-focused research. Ultimately, we seek to help accelerate biopharmaceutical development, while improving therapeutic efficacy and safety. www.gnxtech.com

Contact

Scot R. Weinberger
Founder and CEO
[email protected]

 

GenNext & NeoProteomics Announce Alliance in Biomolecular Footprinting

Companies team-up to promote the use of protein footprinting technologies, products, and contract research services in biopharmaceutical research and development.

Montara, California, June 16th, 2020 – GenNext Technologies (GenNext) and NeoProteomics (Neo) have joined forces to advance biomolecular footprinting know-how and utility in biopharmaceutical and structural biology research. Neo is a world-recognized leader in footprinting software and services for biopharmaceutical and structural biology research. GenNext is the world’s only provider of footprinting instruments, software, and accessories that enable higher order structural analysis in a compact, intuitively simple, benchtop format.

Together, both companies are developing an informative website, proteinfootprinting.com, dedicated to facilitating the rapid exchange of scholarly content and discourse among researchers working in pharmaceutical and biopharmaceutical development as well as structural biological studies. This website will also provide understandable application examples so scientists and decision makers in the field can immediately grasp the impact of protein footprinting upon their research.

As a next step in educating the community, the companies are pleased to announce an upcoming webinar series to disseminate footprinting know-how and highlight its applied value in biopharmaceutical and structural biology research. Five, one-hour information packed webinars are planned to be presented by leaders in the biomolecular footprinting field, including: Professor Mark Chance (Case Western Reserve University), Professor Michael Gross (Washington University, St. Louis), Professor Joshua Sharp (University of Mississippi), and Professor Lisa Jones (University of Maryland Baltimore). The first seminar is scheduled for September 23rd, 2020, with more information found at gnxtech.com/webinar-series.

“We are excited to launch this alliance with NeoProteomics,” remarked Scot Weinberger, President and CEO of GenNext Technologies. “In academic studies, footprinting has provided valuable information by exposing monoclonal antibody defects, elucidating biosimilar failure and storage induced defects, and facilitating the study of orthosteric and allosteric drug-target interactions and protein conformational change. Until now, footprinting has been scantly applied in biopharma due to the inherent complexities of the technique and the absence of facile and reliable commercial products. GenNext provides biopharmas with the world’s first dedicated instrumentation and software products for biopharmaceutical higher order structural studies, which exploit the analytical power of biomolecular footprinting.”

“We too are pleased to align with GenNext Technologies to launch and promote this educational platform.” said John Schenkel, Jr., President and CEO of NeoProteomics. “Over the past few years, we’ve worked with our biotechnology clients and collaborators to demonstrate that protein footprinting is a very precise and versatile biophysical technique, which provides highly significant and actionable data. What’s most exciting however, is the introduction of new technologies which make Protein Footprinting much more accessible. We feel very strongly that by utilizing Protein Footprinting, researchers will be better equipped to attack human disease.”

About GenNext Technologies Inc.

GenNext Technologies, Inc., is an early stage biotechnology services and instrumentation company located in the San Francisco Bay Area. The company is committed to the advancement of biopharmaceuticals by introducing revolutionary new solutions for protein higher order structural analysis. GenNext is developing disruptive technology and products to mature the technique of Hydroxyl Radical Protein Footprinting (HRPF), with the goals of accelerating biopharmaceutical development, reducing biopharmaceutical manufacturing cost, while improving biopharmaceutical patient efficacy and safety. The GenNext team is an accomplished collection of scientists and engineers who have been creating first-in-class life science tools for over thirty years.

About NeoProteomics Inc.

NeoProteomics, Inc. (Neo), is a Cleveland, Ohio based contract research organization, founded in 2006, by Mark Chance and John Schenkel, Jr. Neo’s team of world-class structural and pharmacological experts specialize in offering high-resolution protein structure characterization services to industrial laboratories looking to accelerate their discovery and drug development programs. Over the past ten years, Neo has been utilizing Protein Footprinting (HRPF) techniques to develop and expand services to help solve biotechnology’s most challenging structural questions including membrane proteins and GPCR’s. Neo services include: epitope – paratope mapping; protein – ligand binding; H2L- lead generation; and expert consulting. For more information, please see www.neoproteomics.net